Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$36.95
▼ $0.70 (-1.9%)
Market data updated: 09/19 11:18 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$7.63B
Day Range
$36.80 - $38.18
52-Week Range
$14.58 - $45.42
Beta
—
Next Earnings
09.11.2026
Support
$36.11
Resistance
$45.42
IMVT is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+139.9% (1Y)
Strengths: 4/23 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 9.09
Risk
Biggest negative driver
DCF Fair Value
Estimated fair value: -$41.65 vs. price $36.95 (-212.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
41
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
32
Quality
No data available
Value
38
Momentum
33
Risk
48
Sentiment
68
Fundamental
46
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Immunovant, Inc. has centered on its **balanced risk/reward profile** following a stock rally, with UBS raising its price target to $40 while maintaining a neutral rating. The company’s **Q1 2027 earnings call** highlighted upcoming **pivotal data readouts** for its lead candidate, IMVT-1402, and a strong cash runway supporting development. While broader pipeline updates were less emphasized, Immunovant remains linked to Roivant Sciences’ broader strategic plans, including potential regulatory milestones in the second half of 2026.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Immunovant, Inc.. News trend score: 68. Reason: 5 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
22
🎯 Conviction (vs. Emotion)
50
Psychology
69
Fundamentals
46
Technical
33
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
+5%
Market Narrative
43
Fundamental Reality
50
Narrative Gap
-7
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a **cautious, non-emotional stance**—no dominant psychological state is active. Negative momentum (-9.4% ROC) and neutral sentiment (50/100) dampen FOMO or euphoria, while modest volatility (1.05x ATR) and lack of extreme RSI (44) prevent panic or overconfidence. The narrative gap (-17) hints at a disconnect between market expectations and fundamentals, but no clear bias drives trading. The key question: *Is this a pause before a reversal, or a sustained pullback?*
Updated: 09/09/2026, 05:11 AM
👥 What the crowd believes
"CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development."
"its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch."
"Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says"
"IMVT posts a wider quarterly loss as R&D spending rises"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 2/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect deep methodological clashes between risk tolerance, market timing, and fundamental rigor. Bagehot’s near-perfect score highlights its liquidity resilience, aligning with a credit-focused, defensive lens, while Nelson and Mackay’s high marks suggest cyclical undervaluation and absence of speculative frenzy—both favoring contrarian or value-leaning approaches. Conversely, Graham’s low scores and Livermore’s negative trend verdict underscore its failure to meet traditional defensive or trend-following criteria, while Marks’ mixed assessment hints at a business that may already be priced for optimism. The extreme lows from Housel, Veblen, and Fisher—rooted in volatility aversion, conspicuous consumption critiques, or lack of data—contrast sharply with the cautious optimism of Nelson and Mackay, illustrating how even similar ‘value’ frameworks diverge on risk appetite and market psychology.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 94
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 72
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 62
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 48
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 48
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 47
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 40
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 31
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 2
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 0
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 20%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 0
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A trading range after an advance, but still without clear (volume-based) confirmation of a distribution phase.
Low confidence
$36.11
Range Bottom
$45.42
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-59.3%
ROA
-52.8%
ROIC
—
EPS
-$2.77
Cash
$902.11M
Total Debt
—
Current Ratio
9.09
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Current Price
$36.95
Estimated Fair Value (DCF)
-$41.65
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-212.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $-448.05M | $-411.05M |
| 2 | 8.1% | $-484.45M | $-407.76M |
| 3 | 6.3% | $-514.73M | $-397.47M |
| 4 | 4.4% | $-537.25M | $-380.60M |
| 5 | 2.5% | $-550.68M | $-357.91M |
Base FCF (last actual year)
$-407.32M
Terminal Value
$-8.68B
Present Value of Terminal Value
$-5.64B
Enterprise Value
$-7.60B
Net Debt
$0
Equity Value
$-7.60B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$4.67
Tangible Book Value per Share (Tangible NAV)
$4.67
Sentiment based on basic keywords (not AI) — 5 positive, 13 neutral, 2 negative out of the last 20 articles.
Benzinga · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
SeekingAlpha · 13.9.2026
Yahoo · 10.9.2026
GlobeNewswire · 10.9.2026
Yahoo · 24.8.2026
MT Newswires · 24.8.2026
MT Newswires · 24.8.2026
Yahoo · 13.8.2026
Motley Fool · 13.8.2026
Yahoo · 7.8.2026
MarketBeat · 7.8.2026
Yahoo · 6.8.2026
Moby · 6.8.2026
Yahoo · 6.8.2026
MarketBeat · 6.8.2026
Yahoo · 6.8.2026
Zacks · 6.8.2026
Immunovant, Inc. (IMVT) currently has a StockIQ AI score of 41/100, rated "Weak" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
IMVT currently scores 41/100 (Weak) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, IMVT's estimated fair value is -$41.65, which is 212.7% below the current price of $36.95. This is one valuation model among several signals in the fair-value category, not a price target.
IMVT's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 9.09; Price is above the 200-day average; +2.6% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: Estimated fair value: -$41.65 vs. price $36.95 (-212.7%); Calmar: 0.28 (3y annualized return 19.8% / max drawdown 69.9%); Return on equity (ROE): -59.3% (negative).
StockIQ has no recorded dividend payment history for IMVT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 17 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Pande Atul | Exercise of Derivative Securities | 28.8.2026 | 118,231 | +1,500 | $8.43 |
| Pande Atul | Open Market Sale | 28.8.2026 | 116,731 | -1,500 | $43.27 |
| Pande Atul | Exercise of Derivative Securities | 28.8.2026 | 65,181 | -1,500 | — |
| Pande Atul | Exercise of Derivative Securities | 28.8.2026 | 1,500 | -1,500 | — |
| Pande Atul | Open Market Sale | 28.8.2026 | 1,500 | -1,500 | $43.27 |
| Pande Atul | Exercise of Derivative Securities | 28.8.2026 | 1,500 | +1,500 | $8.43 |
| Gloria Melanie | Open Market Sale | 20.8.2026 | 3,056 | -3,056 | $44.16 |
| Pande Atul | Open Market Sale | 24.7.2026 | 1,500 | -1,500 | $39.80 |
| Pande Atul | Exercise of Derivative Securities | 24.7.2026 | 1,500 | +1,500 | $8.43 |
| Pande Atul | Exercise of Derivative Securities | 24.7.2026 | 1,500 | -1,500 | — |
| Pande Atul | Exercise of Derivative Securities | 24.7.2026 | 118,231 | +1,500 | $8.43 |
| Pande Atul | Open Market Sale | 24.7.2026 | 116,731 | -1,500 | $39.80 |
| Pande Atul | Exercise of Derivative Securities | 24.7.2026 | 66,681 | -1,500 | — |
| Stout Jay S | Open Market Sale | 23.7.2026 | 2,857 | -2,857 | $38.69 |
| Girao Tiago | Open Market Sale | 23.7.2026 | 6,798 | -6,798 | $38.69 |
| Girao Tiago | Open Market Sale | 23.7.2026 | 240,798 | -6,798 | $38.69 |
| Stout Jay S | Open Market Sale | 23.7.2026 | 205,341 | -2,857 | $38.69 |
| Van Tuyl Christopher | Open Market Sale | 8.7.2026 | 1,143 | -1,143 | $39.53 |
| Van Tuyl Christopher | Open Market Sale | 8.7.2026 | 63 | -63 | $39.99 |
| Stout Jay S | Open Market Sale | 8.7.2026 | 77 | -77 | $39.99 |
| Stout Jay S | Open Market Sale | 8.7.2026 | 1,906 | -1,906 | $39.53 |
| Gloria Melanie | Open Market Sale | 8.7.2026 | 1,930 | -1,930 | $39.53 |
| Stout Jay S | Open Market Sale | 8.7.2026 | 105 | -105 | $39.99 |
| Gloria Melanie | Open Market Sale | 8.7.2026 | 106 | -106 | $39.99 |
| Stout Jay S | Open Market Sale | 8.7.2026 | 1,399 | -1,399 | $39.53 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
15,784,450 shares short as of 2026-08-31 · vs. 16,375,679 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
61.4% of trading volume this week was short selling, vs. 73.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology